Marker Therapeutics Inc (MRKR)

[lasers]

$TPIV TPIV200 alpha folate receptor vaccine, developed at the Mayo Clinic, has drawn the attention of the DOD and Major Pharma AstraZeneca for P2 trials which IMO great results will follow.

As for TPIV100, Mayo's HER2/neu vaccine no doubt IMO, Mayo and $TPIV R&D techs will be carefully analyzing Galena's NeuVax failed 700 persons P3 data.

Off-the-shelf vaccines are limited as to success as are also off-the-shelf CI. Perhaps 25% success rate each for a combine 50% ORR.

$TPIV new Patented PolyStart vaccine could IMO be expected to increase ORR over the current vaccines.

As well I look forward to Mayo's new autologous FRaDC as the ultimate ORR for vaccines.

https://clinicaltrials.gov/ct2/show/NCT02111941?term=FRaDC&rank=1